Equities researchers at Wedbush issued their Q1 2026 earnings per share (EPS) estimates for Nuvation Bio in a report issued on Thursday, March 6th. Wedbush analyst D. Nierengarten forecasts that the ...

Investment analysts at Wedbush boosted their FY2025 earnings estimates for shares of Fennec Pharmaceuticals in a research ...

In-theater advertising company National CineMedia Inc. is well-positioned to reap the benefits of cinema’s unique proposition ...

Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

Despite the recent sell-off in tech stocks, analysts at Wedbush believe that this downturn is temporary and that AI leaders ...

Tesla stock is gaining ground on the heels of two significant news items today. President Trump made a statement of support for the company and its CEO, Elon Musk, and Wedbush put out analysis ...

Nvidia ( NASDAQ: NVDA) is set to host its annual GTC conference next week and with tech stocks under pressure from tariffs, concerns of a recession and negative sentiment, Wedbush Securities believes ...

Market fears over tariffs and growth have hit tech stocks, but Wedbush sees the dip as a buying opportunity for long-term investors ...

It’s been a bad month for the stock market. But it’s been a terrible month—in fact, a terrible year—for Tesla. Even after ...

Tesla’s (TSLA) innovation machine is still running at full speed. According to Wedbush analyst Daniel Ives, the Electric ...

Tesla ( NASDAQ: TSLA) opened with a 7.9% swing lower on Monday amid broad selling in the stock market to trade at its lowest ...